6 results on '"Moericke, Anja"'
Search Results
2. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
- Author
-
Rizzari, Carmelo, primary, Lanvers-Kaminsky, Claudia, additional, Valsecchi, Maria Grazia, additional, Ballerini, Andrea, additional, Matteo, Cristina, additional, Gerss, Joachim, additional, Wuerthwein, Gudrun, additional, Silvestri, Daniela, additional, Colombini, Antonella, additional, Conter, Valentino, additional, Biondi, Andrea, additional, Schrappe, Martin, additional, Moericke, Anja, additional, Zimmermann, Martin, additional, von Stackelberg, Arend, additional, Linderkamp, Christin, additional, Frühwald, Michael C., additional, Legien, Sabine, additional, Attarbaschi, Andishe, additional, Reismüller, Bettina, additional, Kasper, David, additional, Smisek, Petr, additional, Stary, Jan, additional, Vinti, Luciana, additional, Barisone, Elena, additional, Parasole, Rosanna, additional, Micalizzi, Concetta, additional, Zucchetti, Massimo, additional, and Boos, Joachim, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation
- Author
-
Volkan Hazar, Sema Anak, Brice Mouttet, Sarah Elitzur, Jean-Pierre Bourquin, Martin Schrappe, Benoit Brethon, Luciana Vinti, Jerry Stein, Martin Stanulla, Philip Ancliff, Yöntem Yaman, Ajay Vora, Anja Möricke, Joachim B. Kunz, Christiane Chen-Santel, Nicole Bodmer, Gunnar Cario, Franco Locatelli, Arend von Stackelberg, André Baruche, Mouttet, Brice, Bodmer, Nicole, Bourquin, Jean-Pierre Univ Childrens Hosp Zurich, Pediat Oncol, Zurich, Switzerland, Vinti, Luciana, Locatelli, Franco Sapienza Univ Rome, IRCCS Osped Bambino Gesu, Dept Pediat Haematooncol, Rome, Italy, Ancliff, Philip, Vora, Ajay Great Ormond St Hosp Sick Children, Haematol & Oncol Dept, London, England, Brethon, Benoit, Baruchel, Andre Hop Robert Debre, AP HP, Dept Pediat Hematol, Paris, France, Cario, Gunnar, Moericke, Anja, Schrappe, Martin Christian Albrechts Univ Kiel, ALL BFM Study Grp, Dept Pediat 1, Kiel, Germany, Schrappe, Martin Univ Med Ctr Schleswig Holstein, Kiel, Germany, Chen-Santel, Christiane, von Stackelberg, Arend Charite, Dept Pediat Oncol Hematol, Berlin, Germany, Elitzur, Sarah Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr, Pediat Hematol Oncol, Tel Aviv, Israel, Hazar, Volkan, Yaman, Yontem, Anak, Sema Medipol Univ Hosp, Dept Pediat Hematol, Istanbul, Turkey, Kunz, Joachim Heidelberg Univ, Pediat Oncol Hematol & Immunol, Heidelberg, Germany, Stein, Jerry Tel Aviv Univ, Sackler Fac Med, Schneider Childrens Med Ctr, Bone Marrow Transplant Unit, Tel Aviv, Israel, Schrappe, Martin Christian Albrechts Univ Kiel, Univ Med Ctr, Pediat, Kiel, Germany, Stanulla, Martin Hannover Med Sch, Pediat Hematol & Oncol, Hannover, Germany, University of Zurich, and Bourquin, Jean-Pierre
- Subjects
Oncogene Proteins, Fusion ,Oncogene Proteins ,2720 Hematology ,610 Medicine & health ,EDDY ,Antineoplastic Agents, Immunological ,Text mining ,immune system diseases ,hemic and lymphatic diseases ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Antibodies, Bispecific ,medicine ,Homologous chromosome ,Humans ,Transplantation, Homologous ,Combined Modality Therapy ,Online Only Articles ,Mandibular Molar ,business.industry ,Hematopoietic Stem Cell Transplantation ,Consolidation Chemotherapy ,Hematology ,Transplantation ,Treatment Outcome ,10036 Medical Clinic ,Smear Layer ,Cancer research ,Blinatumomab ,Debris ,Stem cell ,business ,Root Canal Preparation ,medicine.drug - Abstract
WOS: 000469839300005 PubMed ID: 30765470 TCF3-HLF-positive leukemia represents a rare subtypeof childhood acute lymphoblastic leukemia (ALL), characterized by a high rate of treatment failure despite treatment intensification and allogeneic stem cell transplantation (SCT). Given the high and homogeneous expressionof CD19 on blast cells of this leukemia subtype, thesepatients may benefit from CD19-directed immunotherapy. Here, we report the experience on nineTCF3-HLF-positive ALL patients, most of whom weretreated early in first consolidation with blinatumomab asa bridge to SCT between 2015 and 2018. Treatment withblinatumomab was generally well tolerated; reversibleneurotoxicity was observed in two patients. All ninepatients achieved molecular remission after blinatumomab treatment; seven underwent SCT and for onepatient SCT is planned. Median follow up after start ofblinatumomab treatment was 342 days, and four patientsremain in molecular remission after a follow up of 1317,1292, 1245, and 342 days, respectively. Three patientsdied because of infectious complications not directlyrelated to blinatumomab, because they occurred eitherafter SCT or after emergence of a CD19-negativeleukemia clone. In the light of these encouraging observations, CD19-directed immunotherapy should be considered early after induction chemotherapy inTCF3-HLF-positive ALL children and patients’ outcomemonitored systematically by study groups.
- Published
- 2019
4. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.
- Author
-
Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Göhring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, and Biondi A
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, B-Lymphocytes, Child, Humans, Neoplasm, Residual, Prognosis, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
ABL-class fusions other than BCR-ABL1 characterize around 2-3% of precursor B-cell acute lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes have a dismal outcome and may benefit from the introduction of tyrosine kinase inhibitors. We analyzed clinical characteristics and outcome of 46 ABL-class fusion positive cases other than BCR-ABL1 treated according to AIEOP-BFM (Associazione Italiana di Ematologia-Oncologia Pediatrica-Berlin-Frankfurt-Münster) ALL 2000 and 2009 protocols; 13 of them received a tyrosine kinase inhibitor (TKI) during different phases of treatment. ABL-class fusion positive cases had a poor early treatment response: minimal residual disease levels of ≥5×10
-4 were observed in 71.4% of patients after induction treatment and in 51.2% after consolidation phase. For the entire cohort of 46 cases, the 5-year probability of event-free survival was 49.1+8.9% and that of overall survival 69.6+7.8%; the cumulative incidence of relapse was 25.6+8.2% and treatment-related mortality (TRM) 20.8+6.8%. One out of 13 cases with TKI added to chemotherapy relapsed while eight of 33 cases without TKI treatment suffered from relapse, including six in 17 patients who had not received hematopoietic stem cell transplantation. Stem cell transplantation seems to be effective in preventing relapses (only three relapses in 25 patients), but was associated with a very high TRM (6 patients). These data indicate a major need for an early identification of ABL-class fusion positive acute lymphoblastic leukemia cases and to establish a properly designed, controlled study aimed at investigating the use of TKI, the appropriate chemotherapy backbone and the role of hematopoietic stem cell transplantation. (Registered at: clinicaltrials.gov identifier: NTC00430118, NCT00613457, NCT01117441) ., (Copyright© 2020 Ferrata Storti Foundation.)- Published
- 2020
- Full Text
- View/download PDF
5. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
- Author
-
Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, and Karawajew L
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Chromosome Aberrations, Female, Humans, Immunophenotyping, Induction Chemotherapy, Infant, Leukocyte Common Antigens genetics, Male, Mutation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma mortality, Prognosis, Receptors, Cytokine genetics, Receptors, Cytokine metabolism, Receptors, Interleukin-7 genetics, Receptors, Interleukin-7 metabolism, Receptors, Purinergic P2Y genetics, Receptors, Purinergic P2Y metabolism, Recurrence, Treatment Outcome, Leukocyte Common Antigens metabolism, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism
- Abstract
Further improvement of outcome in childhood acute lymphoblastic leukemia could be achieved by identifying additional high-risk patients who may benefit from intensified treatment. We earlier identified PTPRC (CD45) gene expression as a potential new stratification marker and now analyzed the prognostic relevance of CD45 protein expression. CD45 was measured by flow cytometry in 1065 patients treated according to the ALL-BFM-2000 protocol. The 75(th) percentile was used as cut-off to distinguish a CD45-high from a CD45-low group. As mean CD45 expression was significantly higher in T-cell acute lymphoblastic leukemia than in B-cell-precursor acute lymphoblastic leukemia (P<0.0001), the analysis was performed separately in both groups. In B-cell-precursor acute lymphoblastic leukemia we observed a significant association of a high CD45 expression with older age, high initial white blood cell count, ETV6/RUNX1 negativity, absence of high hyperdiploidy (P<0.0001), MLL/AF4 positivity (P=0.002), BCR/ABL1 positivity (P=0.007), prednisone poor response (P=0.002) and minimal residual disease (P<0.0001). In T-cell acute lymphoblastic leukemia we observed a significant association with initial white blood cell count (P=0.0003), prednisone poor response (P=0.01), and minimal residual disease (P=0.02). Compared to CD45-low patients, CD45-high patients had a lower event-free survival rate (B-cell-precursor acute lymphoblastic leukemia: 72 ± 3% versus 86 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 60 ± 8% versus 78 ± 4%, P=0.02), which was mainly attributable to a higher cumulative relapse incidence (B-cell-precursor acute lymphoblastic leukemia: 22 ± 3% versus 11 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 31 ± 8% versus 11 ± 3%, P=0.003) and kept its significance in multivariate analysis considering sex, age, initial white blood cell count, and minimal residual disease in B-cell-precursor- and T-cell acute lymphoblastic leukemia, and additionally presence of ETV6/RUNX1, MLL/AF4 and BCR/ABL1 rearrangements in B-cell-precursor acute lymphoblastic leukemia (P=0.002 and P=0.025, respectively). Consideration of CD45 expression may serve as an additional stratification tool in BFM-based protocols. (ClinicalTrials.gov identifier: NCT00430118).
- Published
- 2014
- Full Text
- View/download PDF
6. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.
- Author
-
Krieger D, Moericke A, Oschlies I, Zimmermann M, Schrappe M, Reiter A, and Burkhardt B
- Subjects
- Adolescent, Ataxia Telangiectasia Mutated Proteins, Child, DNA, Neoplasm genetics, Female, Genetic Markers genetics, Humans, Leukemia, T-Cell mortality, Leukemia, T-Cell pathology, Loss of Heterozygosity genetics, Male, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma mortality, Survival Rate trends, Cell Cycle Proteins genetics, Cyclin-Dependent Kinase Inhibitor p15 genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, DNA-Binding Proteins genetics, Genetic Loci genetics, Leukemia, T-Cell genetics, Microsatellite Repeats genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, Protein Serine-Threonine Kinases genetics, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Proteins genetics
- Abstract
Although deletions of cell cycle regulatory gene loci have long been reported in various malignancies, little is known regarding their relevance in pediatric T-cell lymphoblastic lymphoma (T-LBL) and T-cell lymphoblastic leukemia (TALL). The current study focused on loss of heterozygosity (LOH) analyses of the CDKN2A/B (chromosome 9p), ATM (chromosome 11q) and p53 (chromosome 17p) gene loci. Frequencies of LOH were compared in 113 pediatric T-LBL and 125 T-ALL who were treated uniformly according to ALL-BFM strategies. Furthermore, LOH findings were correlated with clinical characteristics and tested for their prognostic relevance. LOH at 9p was detected in 47% of T-LBL and 51% of T-ALL, and was associated with male gender in both. In T-ALL, LOH at 9p was associated with favorable initial treatment response. A tendency for favorable event-free-survival was observed in LOH 9p positive T-LBL. The frequency of LOH at chromosomes 11q and 17p was 5% or less for both diseases.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.